Market Overview

Kamada Says Meets Primary Endpoint Of U.S. Phase 2 Study Of Inhaled Alpha-1 Antitrypsin for Treatment Of Alpha-1 Antitrypsin Deficiency

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News

 

Related Articles (KMDA)